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Running head: Improving the management of APL 
 
Abstract 
Acute promyelocytic leukemia (APL) is highly curable. To achieve high cure rates, targeted 
therapy with retinoic acid (ATRA) must be started promptly at time of suspected diagnosis. 
Early death rates (EDRs, ≤30 days from diagnosis) differ markedly in patients treated on 
clinical trials compared to the general population.   
Objectives and methods: We used the comprehensive Danish National Acute Leukemia 
Registry (DNLR) to investigate the incidence, treatment, EDR, and long-term clinical 
outcome in APL between 2000 and 2014.  
Results: Twenty-two of 41 deaths occurring in 122 APL patients were EDs which were 
primarily caused by intracranial hemorrhage, disseminated intravascular coagulation (DIC), 
sepsis, and multiorgan failure. The overall EDR was 18.0%, whereas clinical trial participants 
had an EDR of 6.7%. Fifteen patients recruited to the NCRI AML17 APL trial from 2010 to 
2013 were younger and had decreased mortality (HR 0.18, CI 0.04 – 0.86, p=0.02) compared 
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to contemporarily treated patients (n = 15) not recruited to a clinical trial. Performance 
status, leukemia origin, and Sanz-score were independent prognostic variables.  
Conclusions: The very low EDR for on-trial patients is not observed in the general cohort of 
APL patients. Diagnostic awareness emerges as the greatest clinical challenge in 
management of APL.  
 
Key words: Acute Promyelocytic Leukemia, Early Death, Diagnostic Awareness, Prognosis  
 
Introduction  
Since the introduction of all-trans retinoic acid (ATRA) in the treatment of APL nearly 30 years ago, 
outcomes have improved significantly. When used as a single agent, ATRA induces complete 
remissions in more than 90% of treated patients but remissions are short lived.1 Over the last 
decades improved long-term outcomes have been obtained by combining ATRA with 
chemotherapeutic agents – in particular anthracyclines  - as in the ATRA and idarubicin regimen 
(AIDA).2,3 More recently, we showed that in de novo APL patients, mainly treated with ATRA in 
combination with anthracyclines, survival reverts to normal after only three months of treatment, 
whereas survival of non-de novo APL patients remains inferior.4 Pivotal studies have demonstrated 
the superiority of arsenic trioxide (ATO) in combination with ATRA for all APL patients in all risk 
groups.5-9 ATO in combination with ATRA is now approved by both the European Medicines Agency 
(EMA) and the U.S. Food and Drug Administration (FDA) for use as first line therapy in adult patients 
with low- and intermediate risk APL and as second line therapy in relapsed APL patients.10,11   
Although the ATO and ATRA-regimen in some studies   appears to be efficient and well-tolerated in 
pediatric APL patients, it is still not recommended in children.12,13 The ability to generalize the results 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
of recent clinical trials has been debated. In a single institution retrospective analysis, significant EDR 
differences were reported between patients recruited to clinical trials and patients treated off trial 
(3% and 21%, respectively).14 
 In addition, while early death rates in clinical trials are reported to range between 2 and 9%, 
broader population-based studies report significantly higher early death rates. Ranging between 
17% and 35%. 
The most common cause of EDR in APL is the hemorrhagic diathesis, primarily due to an increased 
fibrinolysis caused by the secretion of plasminogen activators and lysosymal enzymes of the 
leukemic cells.15 The resolution of this specific coagulopathy occurs in parallel with the induction of a 
leukemic remission which in most cases occurs within 30 days from the start of therapy.16 
 
Given the availability of our comprehensive national acute leukemia registry (DNLR),17,18 we sought 
to study of the epidemiology, EDR, and long-term outcome in adult patients with APL treated in 
Denmark  from 2000 through 2014. The aim of the study was to describe the clinical characteristics, 
treatments, short- and long-term clinical outcomes of APL patient in Denmark in search of areas of 
possible improvements and to determine the clinical impact of clinical trial enrollment on the 
outcomes of patients with APL. 
 
Methods 
Study population  
We used the Danish National Acute Leukemia Registry (DNLR) to identify patients diagnosed and 
treated for APL during the 15-year time period 01 January 2000 through 31 December 2014. We 
identified acute leukemia patients fulfilling at least 1 specific diagnostic criterion consistent with 
APL, i.e. patients registered with FAB M3-morphology and/or WHO ICD-O-code 9866/3. Patients 
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fulfilling ≥1 specific diagnostic criterion for APL were included in the study cohort. The diagnostic 
criteria were: presence of the chromosomal translocation t(15;17)(q24;q21), a FISH analysis 
confirming the presence of the PML-RARA fusion gene, and/or a PCR analysis confirming the 
presence of the PML-RARA fusion gene product. Rare variants of APL, i.e. cases of acute leukemia 
with complex rearrangements involving PML-RARA, and cases with t(11;17)(q13;q21), 
t(11;17)(q23;q21), or t(5;17)(q35;q21) were excluded.16,19 
Throughout the study period, the standard of care for treating APL was an ATRA-containing regimen. 
The Danish population (5.6 million in 2014) has free access to tax-supported health-care. Treatment 
of APL is centralized, and patients are treated at only five (increased to six since 2012) university 
hospitals. No treatment of acute leukemia takes place in private hospitals. This registry study was 
approved by the Danish Data Protection Agency (Datatilsynet, Sundhedsdatastyrelsen, approval no. 
2014-41-3204). 
During the study period, ATRA was initiated shortly after clinical suspicion of an APL diagnosis at all 
centers. However, the standard treatment regimen varied between institutions until 2009. Various 
anthracyclines (or anthracenedione) in combination with Ara-C were used in combination with 
ATRA. Since 2009, all centers used AIDA as the standard regimen4. Furthermore, during the period 
January 2010 to October 2013, the Danish centers participated in the UK Medical Research Council 
(MRC)-led randomized phase III study of AIDA versus ATRA and arsenic, the NCRI AML17 APL trial.6  
Definitions and clinical variables endpoints 
The date of diagnosis was the date of the bone marrow aspiration confirming the APL diagnosis. 
Performance status was measured according to the Eastern Cooperative Oncology Group 
(ECOG)/World Health Organization (WHO) scale and grouped as (0, 1, ≥2).20 The Sanz/PETHEMA and 
GIMEMA-risk score was used to separate patients into low- (WBC ≤10 x 109/L and platelet count >40 
x 109/L), intermediate- (WBC ≤10 x 109/L and platelet count ≤40 x 109/L), and high-risk (WBC count 
>10 x 109/L) patients.3  
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Patients were followed until death, emigration or the date of last follow up (18 February 2016). 
Overall survival was calculated as the time from the day of diagnosis until day of death, emigration 
or last follow up. ED was defined as death within the first 30 days from diagnosis. Very early death 
(VED) was defined as death occurring day 1 through day 7 from date of diagnosis. 
 
Statistical analysis 
Descriptive statistical methods were used to describe the baseline characteristics of the final study 
cohort. We obtained information about the Danish population size per calendar year from Statistics 
Denmark (http://www.dst.dk/en/Statistik) and calculated the annual incidence of APL. We 
compared the prevalence of APL and the distribution of APL/non-APL for calendar years 2000 – 
2004, 2005 – 2009, and 2010 – 2014 using One-way Anova. We compared EDRs by these time 
periods using Kruskal-Wallis test.  
The primary measures of short- and long-term outcome were day 30-mortality and overall survival. 
The Kaplan-Meier method was used to construct estimates of survival curves and survival was 
compared using log-rank test. We used binary regression (relative risk [RR]) to estimate the 
association between patient-associated and leukemia-associated parameters to risk of death within 
30 days (ED). Cox proportional hazards regression (hazard ratios [HRs]) was used to evaluate 
associations between clinical and biological parameters and overall survival. The proportional hazard 
assumption was evaluated and accepted (log minus log plots). Two-sided 95% confidence intervals 
(95% CI) were used throughout.  
All statistical analyses were done using the IBM-SPSS (ver. 20, IBM, Armok, New York, USA) statistical 
package or STATA (ver. 14, Stata Corporation, College Station, Texas, USA). 
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Results  
Overall, 3,836 patients, 15 years of age or older, were registered with an acute leukemia in the 
DNLR. We excluded patients having either a non-APL-acute myeloid leukemia (non-APL AML, 
n=3,401) or acute lymphoblastic leukemia (ALL, n=295). Of the 3,836 acute leukemia patients, 2,134 
(55.6%) were males. The median age at time of diagnosis was 68 years (range 15 – 99 years). Overall, 
3,090 (80.6%) had a cytogenetic analysis performed at time of diagnosis.  
The final study cohort consisted of 122 patients with confirmed APL. The annual incidences of APL 
and non-APL AML were 0.15 and 4.17 per 100,000 per years, respectively. Incidences did not change 
over time (p=0.69 and p=0.20, one-way ANOVA, respectively). Thus, APL comprised 3.5% of all AML 
cases. 
The median age of the APL patients was 51 (range 15 – 83 years). Sixty-seven (54.9%) were male 
patients. The median presenting leukocyte count was 2.5 x 109/L and thirty-seven patients (30.3%) 
had high risk APL (WBC> 10 x 109/L) at diagnosis.  
One-hundred-seven patients had APL arising de novo, and 15 patients had secondary- or therapy-
related APL according to described criteria.21 These 15 patients had APL secondary to treatment for 
breast cancer (6 cases), non-Hodgkin lymphoma (one case), treatment for multiple myeloma (one 
case), myelodysplastic syndrome (one case), and chemotherapy and/or radiotherapy for a variety of 
other cancers (5 cases). Finally, one patient developed APL after mitoxantrone treatment for 
multiple sclerosis. Baseline characteristics are listed in Table 1. 
The methods of diagnostic confirmation are given in Supplementary Table S1. One hundred and two 
(83.6%) cases were confirmed by cytogenetic analysis. Treatment information is also shown in Table 
S1. The most frequently used remission-induction- and consolidation regimen was AIDA, initiated in 
56 (45.9%) of cases. Eight patients (6.6%) enrolled in the NCRI AML17 APL-trial were treated with 
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ATRA and ATO as per protocol. A third of all patients (mainly from the early part of the study period) 
were treated with combinations of ATRA and chemotherapy as per local institutional preference.  
Because the APL diagnosis was not suspected at initial presentation, 10 patients (8.2%) did not receive 
ATRA treatment. Median survival in these 10 patients was median 3.5 days (range: 1 to 1,729 days) 
and only one patient survived beyond day 30. In this single surviving patient, the initial treatment 
regimen (daunorubicin and cytarabine 3 + 10) did not contain ATRA, but ATRA was added to the 
subsequent treatment (AIDA-regimen). In the remaining 9 patients, APL was confirmed when the 
patient was dying or had passed away.  Not receiving ATRA in the primary treatment was associated 
with higher risk of ED (p<0.0001, Fisher’s exact test). 
Autologous stem cell transplantation (SCT) was used in second complete remission in 4 patients with 
APL relapsing after first line treatment. Treatment with allogeneic SCT did not take place in the 
present cohort.   
During 740 person-years observation period, 41 deaths occurred. In Supplementary Table S2 survival 
estimates at day 30, day 90, 1-, 5-, and 10 years are given for patients according to prognostic 
factors. Kaplan-Meier survival plots are shown in Figure 1. Twenty-two of these 41 deaths (53.6%), 
occurred within 30 days from diagnosis, resulting on an EDR of 18.0%. The EDRs in de novo- and in 
non-de-novo APL patients were 16.8% and 26.7%, respectively. Comparing the 5-year time periods 
(2000 – 2004, 2005 – 2009, and 2010 – 2014), no differences in the EDR and overall survival were 
noted (Kruskal-Wallis test and log rank test, respectively).  
 
Very early deaths were primarily caused by intracranial hemorrhage, while deaths occurring day 8 to 
day 30 were primarily caused by multiorgan failure, sepsis, or DIC (Table 2).   
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Late deaths were primarily caused by other cancers (n=4) or other causes (n=4)(Table 2). Notably, 
two patients with de novo APL, initially treated with ATRA and chemotherapy (ATRA, daunorubicin, 
and cytarabine, one case, and ATRA and idarubicin, one case), died from therapy-related acute 
myeloid leukemia (non-APL AML). Only a single patient died from treatment refractory APL (Table 2).  
Supplementary Table S3 shows the association between patient- and leukemia-related factors and 
death within 30 days. WHO/ECOG PS score ≥2 and high Sanz risk score were independently 
associated with increased risk of ED in the adjusted analysis. 
 
The association between risk factors and overall survival are shown in Table 3 and in Figure 1. 
Performance status ≥2, non-de novo APL, and Sanz high risk score were all associated with an overall 
increased risk of death.  
 
A total of 15 Danish patients were recruited to the MRC/NCRI AML 17 trial. During the same time 
period, 15 Danish patients were treated off-protocol. Supplementary Table S4 describes the 
characteristics of APL patients by trial status. None of the off-trial patients received ATO in their 
treatment. Patients treated on-trial were on average 9.1 years younger and had significantly lower 
risk of death (HR=0.18, CI 0.04-0.86). Other clinical parameters were evenly distributed between 
the two groups. 
 
Discussion  
Prompt recognition of suspected APL and timely initiation of ATRA reduce EDR in APL. However, they 
remain the greatest clinical challenge in managing patients with APL. Early death rates in APL treated 
with the ATRA-ATO combination in clinical trials has been reported to range between 2 and 9% 
.5,6,22,23 In contrast, EDRs of 17 to 35% have been reported in non-clinical trial subjects with APL 
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treated with ATRA and chemotherapy.24-28 We found that the overall EDR in our population-based 
national APL cohort was 18% without significant variation throughout the study period.   Lack of or 
delay in ATRA treatment (due to missed/delayed diagnosis) in initial therapy was highly significantly 
associated with dismal outcomes. Additionally, in a subgroup analysis, we show that participation in 
an APL clinical trial was associated with lower EDR and long-term clinical outcome comparable to 
results from published clinical phase III trials.  
 
The baseline characteristics of APL patients in Scandinavian and north European countries are 
strikingly similar. Notably, however, median age at time diagnosis and incidences differ between 
European and American cohorts. In Sweden, the median age of 56 years, and the annual incidence 
rate of 0.15 per 100,000 are strikingly similar to our results and those reported in the Netherlands.29 
In contrast, a US SEER-based cohort had a median age of 44 years and an annual incidence of 0.23 
per 100,000,26 while the mean age at diagnosis was 47.9 years and the age-adjusted incidence rate 
was 0.083 per 100,000 in a Canadian population-based cohort.27 As expected, the annual incidence 
rate of APL in our Danish national AML cohort, which includes only 2% patients of non-western 
origin30, is in line with incidences found in the North European populations and with a lower 
incidence rate than seen in ethnically mixed populations. A higher annual incidence rate in 
populations of southern European, Hispanic, and non-western origin has previously been 
noted.27,31,32  Apart from being of more mixed ethnic composition, the two North-American studies 
included children. However, since APL is extremely rare in children, the inclusion of children is an 
unlikely explanation for these differences.33  
The most frequent cause of ED in our cohort was multiorgan failure, sepsis, and DIC, while 
intracranial bleeding was the dominant cause of death during the first week after diagnosis. 
Considering the population-based setting, the observed EDR of 18% is relatively low compared to 
previous reports. Throughout the study period, a liberal use of platelet transfusions was 
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recommended, and more recently, additional use of supplement with fresh frozen 
plasma/fibrinogen/cryoprecipitate has been recommended by European LeukemiaNet, which may 
explain our findings.16 Also, travel time to a hematological center may affect and explain differences 
in reported EDR. Longer distance may prolong the time from initial presentation of symptoms to a 
correct diagnosis and start of ATRA treatment. In Denmark, the geography is confined with rarely 
more than 100 kilometers to the nearest hospital department with highly specialized hematological 
service. In Sweden, United States, and in Canada this is obviously not the case.  
One main finding of our present study was the striking difference in EDR between trial patients and 
patients treated off-trial.  
Clinical trials often exclude older patients (e.g. patients over 60 years of age) and patients with 
poorer performance status (e.g. patients with ECOG/WHO PS >2). Not surprisingly, patients included 
in the NCRI AML17 APL trial were younger (on average 9.1 years), although other baseline 
characteristics were similar between clinical trial participants and non-participants. It is particularly 
noted, though, that our on-trial patients had PS 0 to 1, whereas two of our off-trial patients had PS 4 
(Table S4). This may have contributed to the worse outcome of the off-trial patients. The APL 
diagnosis was clinically confirmed before trial enrolment and patients too sick to be able to consent 
would not be included in the trial. Importantly, all patients dying before treatment initiation would 
count as off-trial patients thus introducing immortal time bias. Selection of less fit APL patients away 
from clinical trials was recently  reported in a single institution experience.14 Thus, apart from the 
treating physician’s preferences, being old, frail, and very ill may obviously keep patients from trial 
participation. 
Our observation that acute leukemia patients who participate in clinical trial do better than off-trial 
patients, corroborate well with our previous observations that non-APL AML patients with favorable 
characteristics are selected into clinical trials. However, even when adjusting for the baseline 
differences, trial-patients have better outcomes.34 Notably, in our present cohort of 30 APL patients, 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
none of the 15 patients treated off-trial received ATO in their treatment while 8 of the 15 patients 
treated on-trial received ATO and ATRA in combination. This difference in treatment may very well 
have contributed to the better outcome of on-trial patients. In our cohort, two cases of therapy 
related neoplasms (non-APL AML) were observed in patients after ATRA and anthracycline-
containing chemotherapy for de novo APL, which may be another clinical benefit from eliminating 
anthracyclines from APL regimens.6,8  
An evident strength of the present study is that we have data from a complete and truly population-
based cohort of APL patients with complete and long-term follow-up, encompassing both trial 
participants and non-trial participants. This study has, however, a number of limitations. These 
include the small number of patients, the limited number of events due to the favorable prognosis, 
the various treatment regimens used during the first part of the study period (supplementary Table 
S1), and the limited number of details in DNLR concerning causes of death including ED (multi organ 
failure/sepsis/DIC being combined into one entity, Table 2), all limiting the analytic possibilities. 
Though the coverage and accuracy of AML diagnoses including APL diagnosis in the DNLR has been 
shown to be close to 100%, probably some APL patients remain undiagnosed. However, as for any 
population-based report, it is likely that some undiagnosed APL patients may die from intracranial 
hemorrhage or DIC prior to or during admission in non-hematological departments. Additionally, 
though only 20% of patients are diagnosed with acute leukemia without a cytogenetic analysis being 
performed, we cannot rule out misclassification of some APLs as non-APLs. These unaddressed 
issues will all tend to underestimate the true EDR in APL. 
The current very efficacious targeted treatment regimens yield cure-rates of more than 90 % in 
patients treated within clinical trials. Consequently, the room for improvement of the prognosis in 
APL patients seems dependent on a high degree of clinical awareness, prompt initiation of ATRA 
treatment, and a rapid confirmation of the diagnosis. Undoubtedly, more APL patient lives can be 
saved by improving diagnostic awareness, while further survival benefits from new treatment 
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regimens may be less obtainable. Initiatives to reduce EDR are greatly warranted. Raising awareness 
of the diagnosis in non-hematological specialties and keeping a stock of ATRA capsules, at all times, 
in emergency wards may be means to decrease early death rates in APL.  
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Legends for figures 
 
Legend for Figure 1. 
Kaplan-Meier survival plots in 122 APL patients. (A) All 122 patients. (B) By age (p=0.002). 
(C) By APL-type (de novo n=107, non-de novo n=15, p=0.015). (D) By Sanz risk score 
(p=0.006). (E) By ECOG/WHO performance status (p<0.0001). (F) By trial participation status 
in 30 patients (years 2010 to 2013, p=0.02). Numbers at risk are indicated at 1-, 5-, and 10 
years. Number of events between time-points are given in parenthesis. 
  
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 1.  
Patient characteristics at time of diagnosis in 122 patients with confirmed acute promyelocytic 
leukemia 
 
Age (years)  
  Mean:  49.3 (range 15-83) 
  Median: 51 (range 15-83) 
  60 years or older: 40 patients 
Sex (122 patients) 
  Male: 67 (55%) 
  Female: 55 (45%) 
White blood cell count (WBC; x109 per L)* 
  Mean: 13 (range: 0.2-99.0) 
  Median: 2.5 (range: 0.2-99.0) 
  Unknown or missing: 3 patients 
Peripheral blood platelet count (x109 per L)* 
  Mean: 39(range: 5-168) 
  Median: 27 (range: 5-168) 
  Unknown or missing: 3 patients 
Sanz risk score (Sanz et al., 2000), no. (%)* 
  Low: 33 (27%) 
  Intermediate: 49 (40%) 
  High: 37 (30%) 
  Unknown or missing: 3 (3%) 
Leukemia origin, no. (%) 
  De novo APL 107 (88%) 
  Non-de novo APL 15(12%) 
ECOG/WHO performance status no. (%) 
  0: 53 (43%) 
  1: 49 (40%) 
  2: 9 (7%) 
  3: 5 (4%) 
  4: 6 (5%) 
Percentages are rounded. *:3 missing.  
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Table 2.  
Time- and cause of death in 41 cases of APL* 
 Day 1 – 7 Day 8 – 30 Day 31 – 90 Day 91 - ∞ Total 
Multi organ 
failure/sepsis/DIC 
3 (7%) 6 (15%) 2 (5%) 0 11 (27%) 
Intracranial bleeding 4 (10%) 1 (2%) 1 (2%) 0 6 (15%) 
Death during chemotherapy, 
NOS 
3 (7%) 2 (5%) 1 (2%) 0  6 (15%) 
Treatment-refractory or 
progressive disease 
0  2 (5%) 2 (5%) 1 (2%) 5 (12%) 
Other cancer (not leukemia) 0 0 0 4 (10%) 4 (10%) 
Not leukemia related 0 0 0 4 (10%) 4 (10%) 
Therapy related AML (t-AML,  
not APL) 
0 0 0 2 (5%) 2 (5%) 
Treatment-related in CR 0 0 1 (2%) 0 1 (2%) 
APL relapse after autologous  
stem cell transplantation  
0 0 0 1 (2%) 1 (2%) 
Unknown or missing 0  1 (2%) 0 0 1 (2%) 
Total 10 (24%) 12 (29%) 7 (17%) 12 (29%)  41 (100%) 
*: Percentages are rounded. 
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Table 3.  
Cox proportional hazards regression analysis of factors of importance to overall survival (OS) in 122 
APL patients*  
 Crude Hazard Ratio (95%CI) Adjusted Hazard Ratio (95%CI) 
Age 
  < 60 years 
  ≥ 60 years 
 
1 (reference) 
2.54 (1.37– 4.69) 
 
1 
1.70 (0.87-3.32) 
White blood cell count (x109 per L) 
  ≤10 
  >10 
 
1 (reference) 
2.46 (1.32-4.56) 
 
ND** 
Platelet count (x109 per L) 
  >40 
  ≤40 
 
1 (reference) 
1,61 (0.78-3.30) 
 
ND** 
Sanz risk score 
  Low 
  Intermediate 
  High 
 
1 (reference) 
1.38 (0.56-3.42)  
3.01 (1.26-7.18) 
 
1 
1.46 (0.57-3.72) 
2.55 (1.04-6.28) 
Leukemia origin 
  De novo APL 
  Non-de novo APL 
 
1 (reference) 
2.45 (1.16-5.16) 
 
1 
2.91 (1.27-6.65) 
WHO PS 
   0 
   1 
   ≥2 
 
1 
2.57 (1.11-5.96) 
9.48 (4.03-22.34) 
 
1 
2.24 (0.96-5.23) 
6.78 (2.81-16.37) 
Sex 
   Women 
   Men 
 
1 (reference) 
1.95 (1.01– 3.80) 
 
1 
1.94 (0.97-3.89) 
*: Three cases with missing data were excluded.  
**: The adjusted analysis included Sanz risk score which is based on WBC and platelet count. 
Number of events during the observation period in the analyzed 119 patients: n = 40. 
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